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An investigation of schizotypy in injecting amphetamine users  
 
Abstract 
 
A fully dimensional view of psychiatric disorder conceptualises schizotypy as both a 
continuous personality trait and an underlying vulnerability to the development of psychotic 
illness.  Such a model would predict that the structure of schizotypal traits would closely 
parallel the structure of schizophrenia or psychosis.  This was investigated in injecting 
amphetamine users (N=322), a clinical population who have high rates of acute psychotic 
episodes and subclinical schizotypal experiences. Schizotypy was assessed using the Oxford-
Liverpool Inventory of Feelings and Experiences (O-LIFE), and psychotic symptoms were 
assessed using the Brief Psychiatric Rating Scale (BPRS).  Using confirmatory factor 
analysis, O-LIFE subscale scores were mapped onto latent variables with their more clinical 
counterparts from the BPRS.  A four-factor model comprising positive schizotypy, 
disorganisation, negative schizotypy, and disinhibition provided the best model fit, consistent 
with prior research into the structure of schizotypy. The model provided a good fit to the data, 
lending support to the theory that schizotypy and psychotic symptoms map onto common 
underlying dimensions. 
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1. Introduction  
The relationship between schizotypy and schizophrenia has been the subject of 
considerable theoretical debate and empirical investigation. In what has been termed the 
“North American tradition” schizotypy has been viewed as quasi dimensional, in which both 
schizotypy and the related construct of schizophrenia fall within a specific category of illness. 
The quasi dimensional component refers to the proposed variations in illness severity that 
occur within this category. A dimensional model reflects the conceptualisation of schizotypy 
as a personality trait normally distributed within the population that extends from non 
pathological manifestations through to psychosis proneness and ultimately to psychosis (see 
Kwapil & Barrantes-Vidal, in press; Claridge, 1997). This dimensional view of psychosis 
predicts that the structure of schizotypy at the trait level closely parallels the structure of 
psychotic or schizophrenic symptoms.   
The underlying factor structure of both schizophrenic symptoms and schizotypal traits 
has been widely investigated, although not in the same clinical groups.  For example 
structural investigations of psychosis point to at least three classes of symptoms labelled 
positive symptoms (perceptual aberrations and unusual beliefs), negative symptoms (blunted 
affect, social anxiety, and lack of close friends), and disorganisation (odd behaviour and 
speech).  When mood symptoms are included in analyses, they seem to constitute a separate 
factor.  Positive and negative symptoms appear to be orthogonal, whereas disorganised and 
positive symptoms are typically correlated (e.g., Peralta & Cuesta, 2000; Peralta & Cuesta, 
2001).   
 The structure of fully dimensional, trait-level schizotypy has also been widely 
investigated and it appears that schizotypy, like schizophrenia, is multidimensional.  
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Mirroring the distinction between positive and negative symptoms in schizophrenia, the two 
most reliable factors that emerge are positive schizotypy (unusual beliefs, magical thinking, 
and perceptual aberrations) and negative schizotypy (anhedonia and a lack of close friends).  
A third group of traits comprising attentional difficulties and social anxiety has sometimes 
loaded on the positive schizotypy factor (Muntaner, Fernandez, & 1988; Raine & Allbutt, 
1989; Venables et al., 1990; Venables, 1990; Kelley & Coursey, 1992), but more often a 
separate factor labelled disorganisation.  When Eysenck’s Psychoticism scale is included, an 
impulsivity factor reliably emerges (Muntaner et al., 1988; Kendler & Hewitt, 1992; Claridge 
et al., 1996). More recent studies of schizotypy measurement have investigated a shortened 
form of the original Chapman’s Wisconsin Schizotypy Scales (WSS), in which original and 
shortened versions of the Magical Ideation, Perceptual Aberration, Social Anhedonia and 
Physcial Anhedonia scales were internally consistent and highly intercorrelated (Gross, 
Silvia, Barrantes-Vidal, & Kwapil, 2012). Later work has found a two-factor model with 
positive and negative symptom dimensions (Kwapil, Ros-Morente, Silva, & Barrantes-Vidal, 
2012). 
Perhaps the largest structural investigation of schizotypy scales was initiated by 
Bentall and colleagues (Bentall, Claridge, & Slade, 1989), who collated 10 existing 
psychosis-proneness scales to form the Combined Schizotypal Traits Questionnaire (CSTQ).  
They reported a four-factor solution, corresponding to cognitive-perceptual (“positive”) 
features, introverted anhedonia (“negative” features, with a strong negative loading for 
Eysenck’s Extraversion), a factor representing a mixture of cognitive disorganisation and 
social anxiety (on which Neuroticism also loaded highly), and a factor labelled impulsive 
nonconformity (defined largely by Eysenck’s Psychoticism and Lie Scales).  Subsequent 
studies using the CSTQ have showed this 4-factor structure to be robust (Mason, Claridge, & 
Jackson, 1995; Claridge et al., 1996).  Mason and colleagues (1995) used these studies to 
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devise their 4-subscale schizotypy instrument: the Oxford-Liverpool Inventory of Feelings 
and Experiences (O-LIFE). In summary, while previous work suggested the existence of a 2-
factor or 3-factor model of schizotypy, more recent research strongly argues for an 
underlying 4-factor structure. 
The comparability between the factor structure of schizophrenia symptoms and 
questionnaire measurement of schizotypy is striking. However, to date, there has not been 
any investigation of the convergence between questionnaire measurement and observed 
schizophrenia-like symptoms. This is a difficult undertaking as nonclinical groups have low 
rates of psychotic symptoms, while people with a psychotic disorder are elevated across most 
proposed dimensions. However, this line of investigation could take place in a sample that 
would be expected to show greater variability in symptoms than either a non clinical group or 
those with schizophrenia. One such group would be regular users of amphetamines. 
Prolonged and high dose use of amphetamines is known to cause psychotic symptoms in 
otherwise healthy humans, and regular users show increased rates of subclinical psychotic-
like experiences such as suspiciousness, hostility and delusional thinking (McKetin et al., in 
press; Lapworth et al., 2009).  If psychotic symptoms lie on a continuum with healthy 
functioning and amphetamine psychosis provides a sound analogue of psychoses in general, 
it is reasonable to assume that amphetamine-induced subclinical psychotic experiences would 
closely resemble high schizotypy.   
The current research makes a unique contribution to the schizotypy literature, by 
investigating the construct in a sample of amphetamine users.  Psychometric properties of the 
O-LIFE have been widely investigated in non-clinical samples, and while such research is 
based on the continuum model of schizotypal traits, there is a problem with low frequencies 
of symptoms in the general population. A sample with higher rates of subclinical symptoms 
of psychosis provides a more sensitive test of schizotypal features, and allows an application 
Schizotypy in Amphetamine Users   6 
 
of observational symptom measures such as the Brief Psychiatric Rating Scale (Ventura, 
Nuechterlein, Subotnik, Gutkind, & Gilbert, 2000), which provide a unique test of the 
convergence between self-report and observational measurement.  
The central aim of the study is to examine relationships between schizotypal traits as 
measured by the O-LIFE, and observed psychiatric symptoms, using confirmatory factor 
analysis (CFA).  Importantly, competing factorial models will be compared, which will help 
to clarify the structure of schizotypy. It is expected that O-LIFE scores and psychiatric 
symptoms will both map onto the four-factor model as described by Ventura et al. (2000), 
adding support for a common structure and for a severity continuum underlying features of 
psychosis.     
2.Method 
 
2.1 Participants and procedure 
Three hundred and twenty nine injecting drug users, who reported that amphetamine was 
their primary drug and had used in the last month were recruited from two needle exchange 
centres in Brisbane, Australia. Interviews were conducted by graduate level psychology 
students trained in the administration of the BPRS. The study received approval from 
participating hospital and university Ethics Committees.  Participants provided informed 
consent, and received A$10 as compensation for their time.  
2.2 Measures  
Following completion of a basic demographic and history questionnaire, participants 
completed measures of recent drug and alcohol use using the calendar based Timeline Follow 
Back procedure (Sobell & Sobell, 1992).  The TLFB method has good test-retest reliability (r 
≥ .79) as well as convergent and divergent validity with other measures of substance use (Fals 
Stewart et al., 2000). Severity of Dependence (SDS; Gossop et al., 1995) was used to assess 
amphetamine dependence with a score > 4 indicative of dependence (Topp & Mattick, 1997).  
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Participants then completed the Oxford-Liverpool Inventory of Feelings and Experiences (O-
LIFE; Mason et al., 1995) containing 104 true/false questions divided into four schizotypy 
scales: Unusual Experiences, Cognitive Disorganisation, Introvertive Anhedonia, and 
Impulsive Nonconformity.  Mason and colleagues  (Mason & Claridge, 2006; Mason et al., 
1995) reported alpha coefficients of between .77 (Impulsive Nonconformity) and .89 
(Unusual Experiences). Test-retest reliability (3-6 month interval) has yielded coefficients 
between .77 and .93 (Burch, Steel, & Hemsley, 1998). Cronbach’s alpha for current study 
was Unusual Experience, .91; Cognitive Disorganisation, .92, Introverted Anhedonia, .85, 
Impulsive Nonconformity, .74.  
 The expanded version of the Brief Psychiatric Rating Scale (BPRS) assesses 24 
different symptoms, measured on a 7 point scale from 1 (not present) to 7 (extremely severe). 
A score of > 4 represents a symptom considered to be of pathological intensity (Lukoff, 
Nuechterlein, & Ventura, 1986). The BPRS can also be used to produce scores on four broad 
symptom domains, positive symptoms (bizarre behaviour, unusual thought content, 
disorientation, hallucinations, and suspiciousness), negative symptoms (blunted affect, motor 
retardation, emotional withdrawal, and self-neglect), manic excitement (motor hyperactivity, 
elevated mood, excitement, distractibility, hostility and grandiosity), and depression/anxiety 
(Ventura et al., 2000). 
2.3 Statistical analysis  
Sociodemographic and clinical characteristics of the sample were analysed using Student’s t 
tests. A series of Confirmatory Factor Analyses (CFA) models involving O-LIFE and Blom-
transformed BPRS scores (Cantrell, Finn, Rickert, & Lucas, 2008; van den Oord et al., 2000) 
were tested.  BPRS items of Disorientation, Bizarre Behaviour, and Motor Retardation were 
excluded from the analyses because they were the most severely skewed with almost all 
participants scoring zero (see Online supplementary material).  
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3. Results 
3.1 Sociodemographic characteristics 
Table 1 and 2 display descriptive statistics for the sample. The majority of the sample was 
male (68%), with a mean age of 29 (SD=7.1) years. Most were single (70%), and 69% were 
unemployed, with the remainder employed (26%) or studying (4%). The vast majority (96%) 
reported being regular users of amphetamines, and 274 (83%) said they were regular users of 
cannabis.  Using an SDS cut-off of  > 4 (Topp & Mattick, 1997), 160 participants (49% of the 
sample) were classified as amphetamine dependent. See Table 3 for correlations between 
OLIFE subscales and BPRS scores and Online Supplementary Material for Correlations 
Between O-LIFE Scale Scores and Selected Blom-Transformed BPRS Symptom Scores.  
There were also significant relationships between the severity of amphetamine dependence 
and measures of psychosis symptomology, particularly so for positive (r = .35) and manic 
symptoms (r = .44).  It is also notable that severity of dependence was also significantly 
correlated with all O-LIFE scales. Thus, the current findings add to a growing body of 
evidence in which there is a clear relationship between amphetamine use and severity of 
psychotic symptomology (McKetin et al., in press).  
Tables 1 and 2  
3.2 Testing a 4-factor model 
Using confirmatory factor analysis, the first tested model was the predicted four-
factor model.  Covariances were drawn between all latent variables because of 
intercorrelations between all O-LIFE scores (See Online Supplementary Material). The 
assumption of multivariate normality was violated (Mardia’s normalised coefficient = 7.27, p 
< .001), but was still acceptable for the purposes of maximum-likelihood (ML) estimation.  
Results indicated that the solution was inadmissible, as the covariance matrix was non-
positive definite (Wothke, 1993).  Closer inspection of results revealed that the latent factor 
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Disorganisation showed standardised covariances of greater than unity (an impossible value) 
for each of the other latent factors (1.45 for Positive Schizotypy, 1.27 for Inhibition, and 1.04 
for Negative Schizotypy), indicating a possible problem with that latent variable.  Further, the 
latent Disorganisation factor accounted for only 3% of the variance in BPRS Conceptual 
Disorganisation, suggesting the BPRS subscale was a poor indicator of the latent factor. 
In the next model, (“4-Factor Mania”), the BPRS Conceptual Disorganisation variable 
was removed leaving the Disorganisation factor defined by only a single variable.  The 
residual error variance was set to 3.942, according to Bollen’s (1989) formula (SD2[1 – 
Cronbach’s α]) for single-indicator latent factors.  Multivariate normality was improved over 
the original model (Mardia’s normalised coefficient = 4.64), although the assumption of 
multivariate normality was still violated.  Therefore, in addition to normed chi-square, the 
Bollen-Stine bootstrap p, a boostrap modification of model chi-square, was also calculated to 
assess model fit. The solution was admissible, but the 4-Factor Mania Model provided a poor 
fit to the data (Table 3).  Notably, the Disinhibition factor accounted for only 3% and 4% of 
the variance in Excitement and Elevated Mood, respectively.  This suggested that these two 
mania items were poor indicators of the Disinhibition factor. 
Because of this poor fit, and given the strong theoretical and empirical support for a 
four-factor model of schizotypal traits (Mason et al., 1995), modifications were made to the 
model (Byrne, 2009).  Substantial improvements were made by correlating two pairs of error 
terms: those for Emotional Withdrawal and Blunted Affect, and those for Suspiciousness and 
Unusual Thought Content (see Figure 1). 
------------- Figure 1 -------------- 
3.3 Modified 4-Factor Model 
The resulting “Modified 4-Factor Model” is shown in Figure 2.  The multivariate 
normality assumption was again violated (Mardia’s normalised coefficient = 5.40, p < .001), 
Schizotypy in Amphetamine Users   10 
 
but was acceptable for ML estimation.  As seen in Table 3, the two modifications provided a 
substantial improvement, with a resulting acceptable fit to the data and best fitting model 
according to the CAIC statistic.  In this model there was only one standardised residual 
covariance above the cutoff of 2.58, which was that between Suspiciousness and Self-Neglect 
(3.81).  The parameter estimates are shown in Figure 2.  All latent factors were moderately to 
strongly intercorrelated (Figure 1).  Positive Schizotypy shared 62% of its variance with 
Disorganisation and 59% with Disinhibition.  Disinhibition also shared 52% of its variance 
with Disorganisation. 
Because the assumption of multivariate normality was violated, all parameter 
estimates were tested with 95% confidence intervals using the bias-corrected bootstrap 
percentile method (1000 samples; Efron, 1988).  Using this correction, all indicator variables 
continued to load significantly on their latent factors.   
------------- Figure 2 -------------- 
3.4  Alternative Models 
In order to bolster confidence in the fit of the hypothesised model, it was compared to 
two alternative, non-hypothesised models (McDonald & Ho, 2002). The alternative 2- and 3-
factor models tested were based both on the observed correlations and prior research 
(Claridge et al., 1996; Kendler & Hewitt, 1992; Kwapil et al., 2012; Muntaner et al., 1988). It 
should be noted that, to ensure the most rigorous comparison, the 2- and 3-factor models also 
omitted BPRS Conceptual Disorganisation and included the same residual covariances as the 
Modified 4-factor Model. That is, they benefited from the same modifications that were made 
to the 4-factor model to improve fit. Because of the high degree of shared variance between 
Positive Schizotypy and Disorganisation, the 3-factor model was analysed with these two 
latent factors collapsed into a single “Positive Schizotypy” factor (see Figure S1).  Although 
Cognitive Disorganisation loaded strongly onto the Positive Schizotypy factor and the model 
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approached acceptable fit, CAIC scores suggest that the model provided a poorer, less 
parsimonious fit to the data than did the Modified 4-Factor Model (see Table 3). The 2-Factor 
Model specified a Positive Schizotypy and Negative Schizotypy factor (see Figure S2).  As 
can be seen in Table 3, this model provided similar fit to the 3-Factor Model, and was also a 
poorer fit than the Modified 4-Factor Model.  Taken together, these findings provided further 
support for the Modified 4-Factor Model. 
Table 3  
4. Discussion 
 The current study makes a significant contribution to the investigation of schizotypy, 
by testing the underlying structure of the construct using self-report and observational 
measures in a clinical population. The current sample of injecting amphetamine users was 
experiencing a range of symptoms. Using a score of four or greater (moderate to severe), 
approximately 14% of the sample reported scoring at least moderately on one positive 
symptom score; 24% for manic excitement, and over 30% on depression or anxiety. The 
current investigation provided further support for the four-factor structure of schizotypal 
traits when measured with the O-LIFE.  The most robust (and the least correlated) factors in 
the four-factor model were positive and negative schizotypy.  Each factor was defined by its 
relevant O-LIFE scale (Unusual Experiences and Introvertive Anhedonia respectively) as 
well as three psychiatric symptoms (although in the case of emotional withdrawal, only 
marginally).  There can be little doubt from the results of this study that Unusual Experiences 
relates to positive symptoms and Introvertive Anhedonia relates to negative symptoms, and 
our data suggests that these relationships exist because each pair taps an underlying, 
continuous latent construct.  The results for the other two O-LIFE scales, however, are more 
equivocal. Further model testing was undertaken to ensure that the 2 and 3 factor structure 
did not provide a better fit for the data.  Notably these models were tested with the same post-
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hoc modifications as the 4-factor model. That is, they were afforded the same “flexibility” 
that the 4-factor model was to provide the most rigorous test possible.  
 A weakness of the model was the failure to find a BPRS symptom that mapped onto 
the Disorganisation factor with the O-LIFE Cognitive Disorganisation subscale, which 
Mason and Claridge (2006) suggest relates to thought disorder and other disorganised 
psychotic symptoms.  The two most obvious candidates here were disorientation and 
conceptual disorganisation, a measure that is proposed to correspond to thought disorder 
(Lukoff et al., 1986). However, the former was highly skewed whilst the latter showed very 
little variability, and its inclusion in the model resulted in a non-positive definite covariance 
matrix.   
Further, the correlations between conceptual disorganisation and both Unusual 
Experiences and Impulsive Nonconformity were weak (r =.19 and r = .12 respectively).  
While this is in line with the BPRS principal components analysis conducted by Ventura et 
al. (2000), which found that conceptual disorganisation crossloaded (about .30) on both 
positive symptoms and manic symptoms, it is not consistent with the hypothesis that 
Cognitive Disorganisation represents an attenuated variant of formal thought disorder.  
This leaves the question of exactly what Cognitive Disorganisation measures, and within a 
dimensional model what its more severe clinical counterpart might be.  Although Cognitive 
Disorganisation was significantly correlated with several BPRS psychotic symptoms (most 
notably the positive symptoms), there were no psychotic symptoms with which it correlated 
more highly than any other O-LIFE subscale.  It did, however, correlate more strongly with 
anxiety and depression than did the other O-LIFE scales. This is consistent with previous O-
LIFE studies which show that Cognitive Disorganisation is strongly related to Eysenck’s 
Neurotism dimension (Mason et al., 1995; Claridge et al., 1996). This does not mean that 
Cognitive Disorganisation is not applicable to schizotypy – the scale shared over 50% of its 
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variance with Unusual Experiences in the present study and, social anxiety is a recognised 
symptom of SPD – but the data suggest that high scorers on this dimension may be at risk of 
developing an anxiety or mood disorder rather than a psychotic disorder. 
 In line with a unitary theory of psychosis, the Impulsive Nonconfirmity scale of the 
OLIFE has been proposed to reflect a broader construct of psychosis proneness, in which 
schizophrenia and bipolar disorder have symptom overlap and a common biological 
susceptibility (Mason & Claridge, 2006). Although significant correlations were obtained 
between Impulsive Nonconformity and BPRS Mania, the 4-factor Mania model did not 
provide an adequate fit of the data. However, removing elevated mood and excitement and 
leaving only hostility in the model resulted in improved fit and successfully mapped onto the 
disinhibition factor.  Thus, it is possible that the disinhibition factor may reflect antisociality 
and aggression rather than psychosis proneness characterised by mania-type symptoms. 
Notably, however, BPRS mania items were also highly correlated with Unusual Experiences, 
which is consistent with previous research suggesting that hypomanic personality tends to 
cross-load onto these two O-LIFE factors (Mason et al., 1995; Claridge et al., 1996).   
 According to a dimensional model of schizotypy, personality traits are normally 
distributed in the general population and, despite resembling attenuated psychotic symptoms, 
are proposed to be adaptive in moderate levels.  While the present study did not provide data 
on the potential adaptability of schizotypal traits, it constituted a test of the continuity 
hypothesis, by investigating both schizotypy and psychiatric symptoms in a sample of 
amphetamine users.  Interestingly, schizotypal personality traits shared predictable 
relationships with their corresponding psychiatric symptoms providing support for the 
dimensional model of schizotypy.   
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Figure 1.  The 4-factor mania model. 
Note.  Ellipses represent latent constructs, rectangles represent observed variables, and circles represent 
residuals.  Numbers above and to the right of observed variables represent the amount of variance explained.  
Parameter estimates are standardised values.  The residual error variance for the observed O-LIFE variable 
Cognitive Disorganisation has been constrained to 3.942, according to Bollen’s (1989) formula (SD2[1 – α]).  
This value is not standardised 
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Figure 2: The modified 4-factor model of schizotypy. 
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